ISBT Working Party on Platelet Immunobiology
Subcommittee on Quality
June 1st, 2018, 2:15 pm – 3:30 pm, Metro Toronto Convention Center, Room 711

Attendees:
China: Guo-Guang Wu (Nanning); France: Rachel Petermann (Paris); Japan: Junko Nakamura (Tokyo), Mika Matsuhashi (Red Cross); Hong Kong: Tony Yan (Queen Mary Hospital); Norway: Maria Therese Ahlen (Tromso); United States: Brian Curtis (Milwaukee, WI), Gayle Teramura (Seattle, WA).

	Summary	Actions
1.	The Subcommittee discussed various aspects of quality as they apply to the ISBT Platelet Immunology Workshops, and the group decided to focus on 4 issues at this time: the structure of future workshops; standardization of CD36 antibody detection; produce a HPA-15 antibody standard, create a mechanism for labs to obtain "rare" antibody controls.	
2.	The Subcommittee decided to gather information to be used in helping to determine the structure of future platelet workshops (PW). 1. Send out a survey to all lab participants of the 2018 PW asking the following: Which do you prefer for the serology and HPA genotyping portions of future PW? a. Formally grade the results for each lab b. Do not grade the results (keep the current process) 2. Review all past workshop results summaries to look for projects that have been included multiple times but should not be included in future workshops and send recommendations to the Platelet Working Party Chairman. 3.	ISBT Working Party to send survey to all labs. Rachel offered to review her thesis that covers several years of past platelet workshop results. Brian to send Rachel any old workshop summaries she does not have.
3.	Only 35% of labs routinely test for GPIV/CD36 antibodies, and only 48% of labs that do test detected the GPIV antibodies in the 2018 PW. As a result, the Subcommittee recommends inclusion of excercises in the 2020 PW for standardization of GPIV antibody detection.	Guo-Guang Wu to prepare recommendations for Subcommittee review and to provide GPIV reagents for PW.

4.	The group agreed that there is great need for an IgG HPA-15 human antibody standard that can be acquired by labs for use as a positive control and for MAIPA QC. Does any member lab have a large volume of plasma that could be used for this purpose? Alternatively, could a human or chimeric monoclonal be produced?	Brian to e-mail request to all labs for ideas to obtain or produce a reagent.
5.	Input needed from all labs on the need for a mechanism to identify labs that can supply small volumes of "rare" anti-sera, e.g., HPA-4b, HPA-6b, etc.	Maria Therese to provide subcommittee with specifics of this request.
6.	Brian was appointed speaker of the Subcommittee on Quality.	

Minute taker: Brian Curtis